| Entry |
|
|---|
| Name |
Scopolamine (INN);
Transderm scop (TN) |
|---|
| Product |
|
|---|
| Generic |
SCOPOLAMINE (A-S Medication Solutions), SCOPOLAMINE (A-S Medication Solutions), SCOPOLAMINE (Actavis Pharma), SCOPOLAMINE (Ingenus Pharmaceuticals), SCOPOLAMINE (Mylan Pharmaceuticals), SCOPOLAMINE (Rhodes Pharmaceuticals L.P.), SCOPOLAMINE (Zydus Lifesciences Limited), SCOPOLAMINE (Zydus Pharmaceuticals USA), SCOPOLAMINE TRANDERMAL SYSTEM (Bryant Ranch Prepack), SCOPOLAMINE TRANDERMAL SYSTEM (Bryant Ranch Prepack), SCOPOLAMINE TRANDERMAL SYSTEM (Bryant Ranch Prepack), SCOPOLAMINE TRANDERMAL SYSTEM (Bryant Ranch Prepack), SCOPOLAMINE TRANSDERMAL SYSTEM (Padagis Israel Pharmaceuticals) |
|---|
| Formula |
C17H21NO4
|
|---|
| Exact mass |
303.1471
|
|---|
| Mol weight |
303.35
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Source |
Atropa belladonna [TAX: 33113]
|
|---|
| Class |
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
Gastrointestinal agent
DG01762 Antiemetic
|
|---|
| Remark |
| Product (DG00065): | D00138<US> |
|
|---|
| Efficacy |
Antiemetic, Mydriatic, Muscarinic acetylcholine receptor antagonist |
|---|
| Comment |
Tropane derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07220 | Cholinergic and anticholinergic drugs |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A04 ANTIEMETICS AND ANTINAUSEANTS
A04A ANTIEMETICS AND ANTINAUSEANTS
A04AD Other antiemetics
A04AD01 Scopolamine
D00138 Scopolamine (INN) <US>
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05C HYPNOTICS AND SEDATIVES
N05CM Other hypnotics and sedatives
N05CM05 Scopolamine
D00138 Scopolamine (INN) <US>
S SENSORY ORGANS
S01 OPHTHALMOLOGICALS
S01F MYDRIATICS AND CYCLOPLEGICS
S01FA Anticholinergics
S01FA02 Scopolamine
D00138 Scopolamine (INN) <US>
USP drug classification [BR:br08302]
Antiemetics
Antiemetics, Other
Scopolamine
D00138 Scopolamine (INN)
Gastrointestinal Agents
Antispasmodics, Gastrointestinal
Scopolamine
D00138 Scopolamine (INN)
Risk category of Japanese OTC drugs [BR:br08312]
Second-class OTC drugs
Inorganic and organic chemicals
Scopolamine
D00138 Scopolamine (INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
DG00065 Scopolamine
D00138 Scopolamine
Gastrointestinal agent
DG01762 Antiemetic
DG00065 Scopolamine
D00138 Scopolamine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Acetylcholine (muscarinic)
CHRM
D00138 Scopolamine (INN) <US>
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01491 Muscarinic cholinergic receptor antagonist
DG00065 Scopolamine
Gastrointestinal agent
DG01762 Antiemetic
DG00065 Scopolamine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 22
1 C1y C 27.2691 -18.1297
2 C1y C 27.5838 -16.9522
3 C1y C 28.4522 -17.8207
4 O2x O 26.2433 -16.7249
5 C1y C 28.7612 -16.6375
6 N1y N 27.5314 -15.3494
7 C1x C 30.3057 -17.8264
8 C1x C 30.0493 -16.6433
9 C1a C 27.4790 -13.9915
10 C1y C 31.3199 -18.3685
11 O7a O 32.3631 -19.2836
12 C7a C 33.7631 -19.2836
13 O6a O 34.4427 -20.4609
14 C1c C 34.4721 -18.0566
15 C8y C 35.8400 -18.0572
16 C8x C 36.5407 -19.2720
17 C8x C 37.9407 -19.2726
18 C8x C 38.6412 -18.0604
19 C8x C 37.9405 -16.8456
20 C8x C 36.5405 -16.8451
21 C1b C 33.7664 -16.8327
22 O1a O 34.4744 -15.6081
BOND 25
1 1 2 1
2 1 3 1
3 1 4 1
4 2 5 1
5 3 6 1
6 3 7 1
7 5 8 1
8 6 9 1
9 7 10 1
10 10 11 1 #Down
11 2 4 1
12 5 6 1
13 8 10 1
14 11 12 1
15 12 13 2
16 12 14 1
17 14 15 1
18 15 16 2
19 16 17 1
20 17 18 2
21 18 19 1
22 19 20 2
23 15 20 1
24 14 21 1 #Down
25 21 22 1
|
|---|